NCT06259981CompletedPhase 2
A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity
Source: ClinicalTrials.gov · Last updated 23 Jan 2025
Brief summary (registry, in English)
This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- First submitted
- 31 Jan 2024
- Start date
- 20 May 2024
- Primary completion date
- 23 Oct 2024
- Lead sponsor
- Glyscend, Inc.
- Diseases
- Obesity
- NCT number
- NCT06259981
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 75
- From 20 May 2024 to the primary completion date, 23 Oct 2024
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treated with any prescription medication or procedure that promotes weight loss or weight gain in the last 6 months
- Use of any drug treatment that affects gastric pH
- Use of any drug treatment that affects gastrointestinal motility
Other illness
- Diagnosis or treatment of any symptomatic or structural abnormality of the GI tract or active disease within 12 months
Lab values
- Known history of any form of diabetes mellitus, or HbA1c ≥6.5% (48 mmol/mol)
Other
- Participants who have had an increase or decrease in body weight more than 5% within the last 3 months
- Clinically significant symptoms (as determined by the Investigator) of nausea, vomiting, bloating, diarrhea, flatulence, constipation, or abdominal pain in the last 30 days
Who the study is looking for
- Male or female, ≥ 18 and ≤ 70 years old at the time of screening
- BMI ≥ 32 and ≤ 40 kg/m² at screening
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mercury Street Medical Coordinator of this site? Confirm its status | Butte | United States | Unknown status |
| Tampa Bay Medical Research, Inc. Coordinator of this site? Confirm its status | Clearwater | United States | Unknown status |
| Tandem Clinical Research Coordinator of this site? Confirm its status | Marrero | United States | Unknown status |
| Sensible Healthcare, LLC Coordinator of this site? Confirm its status | Ocoee | United States | Unknown status |
| Clinical Trials of Texas Inc Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.